- Home
- WHWK vs ANVS Comparison
WHWK vs ANVS Comparison
Compare WHWK & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | ANVS |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 111.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | WHWK | ANVS |
|---|---|---|
| Price | $3.81 | $2.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $13.50 |
| AVG Volume (30 Days) | 146.1K | ★ 337.5K |
| Earning Date | 03-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $1.11 |
| 52 Week High | $4.40 | $5.50 |
Technical Indicators
Market Signals| Indicator | WHWK | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 44.59 |
| Support Level | $1.84 | $2.29 |
| Resistance Level | $4.40 | $2.63 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 58.81 | 10.49 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.